Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
Recap by typeshit. Full story at Medical Xpress.
HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
The Medicare GLP-1 Bridge pilot runs July 2026 through 2027, covering FDA-approved pills and shots with no deductible for eligible Part D enrollees.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
Bell raises the question of muscle loss for people losing weight on a GLP-1 and notes it isn't medical advice, pointing viewers to their doctor.
Loading…